Posttranslational Regulation of Human DNA Polymerase ι

Justyna McIntyre1,2, Mary P. McLenigan1, Ekaterina G. Frank1, Xiaoxia Dai3, Wei Yang4, Yinsheng Wang3 and Roger Woodgate1,*

1 From the Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA

2 From the Institute of Biochemistry and Biophysics, Polish Academy of Sciences, ul. Pawinskiego 5a, 02-106 Warsaw, Poland

3 From the Department of Chemistry, University of California Riverside, Riverside, CA 92521-0403, USA

4 From the Laboratory of Molecular Biology, National Institute of Diabetes, Digestive, Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Running Title: Ubiquitination of polι

To whom correspondence should be addressed: Roger Woodgate, Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA. Tel.: +1-301-217-4040; Fax: Email: woodgate@nih.gov

Keywords: Y-family DNA polymerase, DNA polymerase ι, Post-translational modification, Ubiquitin, Translesion DNA Synthesis, DNA Repair, Mutagenesis

Background: Many proteins are subject to posttranslational regulation, such as ubiquitination.

Results: Human DNA polymerase ι (polι) can be monoubiquitinated at >27 unique sites and exposure to naphthoquinones results in polyubiquitination of polι.

Conclusion: Ubiquitination sites are located across the entire polι polypeptide, as well as various structural motifs.

Significance: Ubiquitination at these sites are likely to alter polι’s cellular functions in vivo.

ABSTRACT

Human DNA polymerases (polς) η and ι are Y-family DNA polymerase paralogs that facilitate translesion synthesis (TLS) past damaged DNA. Both polη and polι can be monoubiquitinated in vivo. PolΗ has been shown to be ubiquitinated at one primary site. When this site is unavailable, three nearby lysines, may become ubiquitinated. In contrast, mass spectrometry analysis of monoubiquitinated polι revealed that it is ubiquitinated at over 27 unique sites. Many of these sites are localized in different functional domains of the protein, including the catalytic polymerase domain, the PCNA-interacting region, the Rev1-interacting region, as well as its Ubiquitin Binding Motifs, UBM1 and UBM2. Polι monoubiquitination remains unchanged after cells are exposed to DNA damaging agents such as UV-light (generating UV-photoproducts), ethyl methanesulfonate (generating alkylation damage), mitomycin C (generating interstrand crosslinks), or potassium bromate (generating direct oxidative DNA damage). However, when exposed to naphthoquinones, such as menadione and plumbagin, which cause indirect oxidative damage through mitochondrial dysfunction, polι becomes transiently polyubiquitinated via K11- and K48-linked chains of ubiquitin and subsequently

http://www.jbc.org/cgi/doi/10.1074/jbc.M115.675769 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.M115.675769

Copyright 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
targeted for degradation. Polyubiquitination does not occur as a direct result of the perturbation of the redox cycle, as no polyubiquitination was observed after treatment with rotenone, or antimycin A, which inhibit mitochondrial electron transport. Interestingly, polyubiquitination was observed after the inhibition of the lysine acetyltransferase, KATB3/p300. We hypothesize that the formation of polyubiquitination chains attached to polι occurs via the interplay between lysine acetylation and ubiquitination of ubiquitin itself at K11- and K48- rather than oxidative damage per se.

INTRODUCTION
In order to survive the constant threat to their genomes from exposure to endogenous and exogenous DNA damaging agents, cells are equipped with an impressive array of DNA repair mechanisms. Yet situations arise where DNA lesions in the genome remain unrepaired and cells are forced to tolerate the DNA damage. One such tolerance mechanism is “translesion DNA synthesis” (TLS)1. During TLS, the high-fidelity replicase, which is unable to traverse the DNA lesion due to its constrained active site, is replaced with a specialized DNA polymerase (pol) with a more spacious active site that can accommodate the damaged DNA (1). Many of the DNA polymerases discovered in the past fifteen years appear to have some capacity to promote TLS. However, the best-characterized TLS polymerases belong to the Y-family of DNA polymerases (2). Y-family DNA polymerases are typified by human polη, which bypasses a thymine-thymine cyclobutane pyrimidine dimer efficiently and with much higher accuracy than any other human TLS polymerases (3). Because of their more spacious active sites (4), the TLS enzymes are also able to accommodate non-canonical Watson-Crick base pairing and are usually much more error-prone than high fidelity replicases when they replicate undamaged DNA (1). In specialized situations, such as during immunoglobulin somatic hypermutation, this creates genetic diversity and leads to high affinity antigen-specific immunoglobulins (5). However, under normal circumstances, random mutagenesis of chromosomal DNA is highly deleterious, often leading to mutagenesis and tumorigenesis in higher organisms.

It is clear, therefore, that the activity of the TLS polymerases needs to be tightly regulated, so that they only gain access to undamaged genomic DNA when appropriate. Previous studies have revealed that the post-translational modification of the TLS polymerases themselves, or their interacting partners, play a major role in regulating their cellular activities [reviewed in (6)]. In particular, both mono- and polyubiquitination appear to play a central role in regulating TLS polymerases since monoubiquitination of the proliferating cell nuclear antigen (PCNA) appears to control the switch between high fidelity replicases and TLS polymerases (7,8). PCNA can, however, be further polyubiquitinated. The addition of K63-linked polyubiquitin chains to PCNA that is monoubiquitinated at K164 leads to a damage avoidance template-switching pathway that in contrast to TLS allows for error-free DNA damage bypass (9,10).

In addition to PCNA, both human polη and polι TLS polymerases are also subject to monoubiquitination (11,12). Attaching a single ubiquitin moiety to one of four lysine residues in the C-terminus of polη blocks the physical interaction between polη and PCNA (12). As a consequence, polη needs to be actively de-ubiquitinated prior to interacting with PCNA and subsequently recruited to a stalled replication fork (12). The cellular role of polη monoubiquitination remains enigmatic. However, our previous results suggest that monoubiquitination of either polη or polι is a pre-requisite for the physical and functional interaction between the two polymerases (13).

Human polι is one of the least accurate DNA polymerases and exhibits a 10,000-fold range in base substitution fidelity depending on the template sequence copied [reviewed in (1)]. Polι has been extensively characterized at the biochemical level (14-19), and its in vivo re-localization in response to DNA damage has been shown (20,21). The enzyme is involved in the error-free bypass of methylglyoxal-induced minor groove lesions, N2-carboxyethyl-2′-deoxyguanosine (22) and a deficiency in polι has
been suggested to cause sensitivity to oxidative and 4-hydroxynonenal DNA damage (23, 24), as well as stimulate UV-induced mesenchymal carcinogenesis (25). However, the primary biological function of pol ι is still far from being understood.

Some assumptions on pol ι’s cellular role can be derived from the various domains/motifs identified in pol ι. The N-terminal part of the protein contains two partly overlapping catalytic domains; a DNA polymerase domain and a dRP lyase domain (26, 27). The core polymerase domain is built of palm, finger, thumb, and little-finger sub-domains (28, 29). The C-terminal portion of the protein is unstructured and devoted to facilitating interactions with a variety of proteins. Similar to other TLS polymerases, pol ι contains a PCNA interacting peptide motif responsible for the interaction with PCNA (30-32) and a Rev1 interacting region (33, 34). It also contains two ubiquitin binding motifs (11).

Typically, the conjugation of ubiquitin to the lysine residue of a substrate protein occurs as a result of a three-enzyme cascade process involving ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3) (35). Ubiquitin contains seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) and is itself a target for further ubiquitination. Indeed, repetitive ubiquitination can establish polyubiquitin chains on a target protein. The length, the type of linkage, and consequent shape of conjugated polyubiquitin chains direct the function and processing of many intracellular proteins [reviewed in (36)]. All types of ubiquitin chains exist in the cell; however, they vary in abundance and functionality. Different types of polyubiquitin chains regulate different biological processes by promoting proteasomal degradation, altering subcellular localization, modulating enzymatic activity and facilitating protein-protein interactions (37).

In the current work, we have used mass spectrometry analysis to identify the lysine residues that can be ubiquitinated in human pol ι. In contrast to PCNA, which is primarily ubiquitinated at K164 and polη, where the ubiquitinated residues are clustered in its C-terminus, the monoubiquitinated residues in pol ι are scattered amongst its various functional domains/motifs. Furthermore, unlike monoubiquitinated polη that is de-ubiquitinated upon UV-irradiation, the level of monoubiquitinated pol ι remains unchanged after exposure to UV, ethyl methanesulfonate, mitomycin C, or potassium bromate. Interestingly, however, after exposure to menadione and structurally related naphthoquinones pol ι is rapidly polyubiquitinated and intracellular levels of both the unmodified and the monoubiquitinated forms of pol ι decrease significantly. We present evidence that pol ι’s polyubiquitination is not in response to oxidative DNA damage per se, but is rather due to the inhibition of KAT3B/p300 dependent acetylation of ubiquitin, which in turn, allows for the formation of K11- and K48-linked polyubiquitin chains on pol ι that subsequently target it for degradation.

**Experimental Procedures**

**Reagents** - 2,3 dimethoxy-1,4-naphthoquinone (DMNQ) was purchased from Enzo Life Sciences and ethyl methanesulfonate, mitomycin C, potassium bromate, menadione, 1,4-naphthoquinone, juglone, plumbagin, L002; rotenone, antimycin A were all purchased from Sigma-Aldrich.

**Mammalian expression plasmids** - Plasmid pJRM46, is a derivative of pCMV6AN-DDK (Origene) which expresses N-terminal FLAG-tagged full-length human pol ι (13). Derivatives with single or multiple K→A, or K→R substitutions were generated by chemically synthesizing appropriate DNA fragments (Genscript) that were subsequently cloned into pJRM46. Plasmid pRK7-POLI-3XFLAG, is a derivative of pRK7 (38), which expresses full-length human pol ι with three C-terminal FLAG-tags. The vector was constructed by inserting three tandem repeats of the FLAG epitope tag (DYKDDDDK) into the BamHI and EcoRI sites of pRK7 to generate pRK7-3×FLAG. The full-length human POLI gene was amplified from HEK293T cells by reverse transcription PCR using primers POLI-S: AAAGCTAGCATGGAGAAGCTGGGGGTGGA, and POLI-AS:
AAAGGATCCTTTATGTCCAATGTGGAAATC T. These primers introduce 5’ NheI and 3’ BamHI sites into the amplicon, which was and subcloned into the XbaI and BamHI sites of the pRK7-3XFLAG vector. A full list of plasmids used in the current study is shown in Table 1.

Plasmid transfection, protein expression and Western blotting – HEK293T cells were plated onto 100 mm culture plates at a seeding density of 3 x 10^6 cells. When cells were ~40 percent confluent, plasmids were transfected into cells using Turbofectin 8.0 according to the manufacturer’s instructions (Origene). Cells were either mock treated, or exposed to a variety of agents twenty-four or forty-eight hours after transfection depending upon the treatment times required. At appropriate times thereafter, cells were gently collected, washed twice with cold Dulbecco’s PBS without calcium or magnesium, and suspended in modified RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM PMSF, 1 mM Na_3VO_4 and Sigma Protease Inhibitor Cocktail and lysed by sonication for 10 seconds. Immediately after sonication, the extracts were clarified by centrifugation at +4°C for 15 minutes in a Sorvall Biofuge Pico at 16,000g. The supernatants (extracts) were transferred to fresh tubes and protein concentrations were measured using the Pierce BCA Assay (Pierce Biotechnology). Cell extracts were kept at +4°C until being separated on a 4-16% gradient SDS PAGE gel. Proteins were transferred to a PVDF membrane and FLAG-tagged pol was visualized using Tropix Western-Star chemiluminescent kit using mouse anti-FLAG monoclonal antibodies (Abnova) followed by secondary anti-mouse antibody (Novagen). Where noted, other antibodies were used as followed: POLI monoclonal antibody (M01), clone 8G9 (Abnova), or polyclonal rabbit antibodies raised against a KLH-conjugated peptide corresponding to the C-terminal 15 amino acid residues of pol (20). Where noted, the level of pol was compared to β-actin present in the extracts, and were visualized using rabbit anti-β-actin antibodies (Cell Signaling Technologies). The intensity of the individual bands was quantified using the ImageJ 1.47 application (NIH, USA).

Mass spectrometry analysis - Purified recombinant N-terminal FLAG-tagged human pol was purchased from Origene Technologies (Rockville, MD) and was supplied at a final concentration of 0.106 mg/ml. Roughly 80% of the total protein represents unmodified FLAG-pol and ~10% represents a slower-migrating modified FLAG-pol (Fig. 1A). A total of 5 µg of the combined FLAG-pol preparation was applied to a 1 mm thick precast 10% polyacrylamide NuPage gel (Life Technologies). Proteins were separated by SDS-PAGE by running the gel at 190 V for 3.75 hours. All subsequent solutions were prepared using ultrapure HPLC water. The gel was lightly stained using the Novex Collodial Blue Staining Kit (Life Technologies), in brand new disposable plastic trays. Unmodified and modified FLAG-pol bands were excised using a brand new hard-backed razor blade under water. Gel fragments were washed 2X with 50% acetonitrile in ultrapure water. Samples were sent to the Harvard Microchemistry Department (Harvard University, MA), where they were analyzed by mass spectrometry as a custom contract service.

pRK7-POLI-3XFLAG (1.5 µg) was transfected into HEK293T cells (70-80% confluence in a 6-well plate) using Lipofectamine 2000 (Invitrogen). After a 48-hour incubation, the C-terminal 3XFLAG-tagged pol protein was isolated and purified using anti-FLAG M2 beads (Sigma). The purified protein was digested with trypsin (Roche) at an enzyme/substrate ratio of 1:50, and subjected to LC-MS/MS analysis.

LC-MS/MS experiments were performed as described previously (39). Briefly, the peptides were separated on an EASY-nLC II and analyzed on an LTQ Orbitrap Velos mass spectrometer equipped with a nanoelectrospray ionization source (Thermo). The trapping column (150 µm × 50 mm) and separation column (75 µm × 120 mm) were packed with ReproSil-Pur C18-AQ resin (3 µm in particle size, Dr. Maisch HPLC GmbH, Germany). The peptide samples were firstly loaded onto the trapping column in CH_3CN/H_2O (2:98, v/v) at a flow rate of 4.0 µl/min, and resolved on the separation column with a 120-min linear gradient of 2-40% acetonitrile in 0.1%
formic acid and at a flow rate of 300 nl/min. The LTQ-Orbitrap Velos mass spectrometer was operated in the positive-ion mode, and the spray voltage was 1.8 kV. The full-scan mass spectra (m/z 300-2000) were acquired with a resolution of 60,000 at m/z 400 after accumulation to a target value of 500,000 in the linear ion trap. MS/MS data were obtained in a data-dependent scan mode where one full MS scan was followed with 20 MS/MS scans.

Results

Sites of ubiquitination in pol ι - It has been previously reported that pol ι is monoubiquitinated in vivo (11). However, at the time that we embarked on these studies, the location of the modified residue(s) had yet to be determined. To identify the site(s) of ubiquitination in pol ι we initially utilized the contract services of the Harvard Microchemistry Department (Harvard University) to provide mass spectrometry analysis of a commercially available preparation of N-terminal FLAG-tagged human pol ι (Origene) (Fig. 1A). The preparation contains a significant amount of a slower migrating protein that cross-reacts with anti-FLAG antibodies, as well as both polyclonal and monoclonal antibodies against pol ι (Fig. 1B). Based upon the earlier work of Bienko et al. (11), we hypothesized that the slower migrating band was likely to be monoubiquitinated pol ι.

Mass spectrometry analysis of the isolated slower-migrating FLAG-pol ι protein indicated it was indeed monoubiquitinated pol ι, which was modified at six unique lysine residues (K248, K522, K526, K530, K549 and K704). Although we had limited mass spectrometry coverage of the very C-terminus of pol ι, we rationalized that the C-terminal K715 residue might also be subject to ubiquitination, since it is most probably localized on the surface of the protein and thus likely to be exposed to ubiquitinating enzymes.

To determine which of the residues might be the primary site of pol ι ubiquitination, we transfected human HEK293T cells with a series of recombinant plasmids carrying FLAG-tagged pol ι each containing a single lysine to alanine substitution (K248A, K522A, K526A, K530A, K549A, K704A and K715A) and checked the extent of pol ι ubiquitination by western blotting and probing with anti-FLAG antibodies. Remarkably most of the pol ι mutants were ubiquitinated at levels comparable to the wild-type protein (Fig. 2A). Interestingly, the largest reduction in ubiquitination occurred in the K715A mutant, which exhibited approximately 60% of the level observed with the wild-type protein, indicating that K715 is indeed a target for ubiquitination. Based on these observations, it appears that none of the seven lysines is an exclusive site of ubiquitination. However, we rationalized that modification at lysines in close proximity to the respective alanine substitution, might mask the effect of individual lysine mutations (e.g., K522, K526 and K530). To test this hypothesis, we determined the extent of ubiquitination of pol ι mutants containing multiple K→A substitutions. This included double (K704A/K715A), quadruple (K522A/K526A/K530A/K549A), and even septuple (K248A/K522A/K526A/K530A/K549A/K704A/K715A) substitutions (Fig. 2B). To our surprise, ubiquitination of pol ι in the septuple mutant was only diminished by ~50% compared to the wild-type protein suggesting the existence of additional ubiquitination sites in pol ι. By analogy to pol η, where a K682A substitution leads to ubiquitination at nearby lysine residues (12), we made K→A substitutions at pol ι residues K237, K245 and K550. Based on the results obtained by Wagner et al. (40), who reported proteome-wide analysis of in vivo ubiquitination sites, we also made K→A substitutions at K267 and K271. However, a duodecuple mutant carrying all 12K→A substitutions did not prevent monoubiquitination of pol ι (Fig. 2B), thereby implying additional sites of ubiquitination in pol ι.

We therefore undertook an independent mass spectrometry analysis approach, this time using C-terminal FLAG-tagged pol ι. Interestingly, we identified six ubiquitination sites in pol ι that were clustered in the N-terminal half of the polymerase (K53, K283, K309, K271, K310 and K320). None of these sites emerged in the original analysis of N-terminal FLAG tagged pol ι performed at the Harvard Microchemistry department and only one residue (K271), was
identified in the earlier studies by Wagner et al. (40).

Thus, by three independent approaches, two specifically focused on pol η (described herein) and one proteome-wide (Wagner et al.), seventeen independent ubiquitination sites in pol η were identified. We were interested in determining if substitutions at these sites would finally block ubiquitination of pol η. Given the close structural proximity of pol K51 and K72 residues to K53 (29), we also made substitutions at these residues. The combined mutant has 19K→A substitutions. We noted that this mutant has altered gel electrophoretic mobility (Fig. 3A) and decided to limit the influence of the multiple alanine substitutions on the global charge of the protein and consequently its structure, so we also generated a 19K→R mutant.

Interestingly, the 19K→A mutant showed 60% higher levels of pol η ubiquitination than the 19K→R mutant (Fig. 3), suggesting that multiple K→A mutations probably changed the structure of pol η and possibly exposed lysine residues that perhaps would not normally be subject to monoubiquitination. We also observed the same effect when comparing the 12K→A to the 12K→R mutants. In light of the fact that the K→R changes in the combined pol mutants reduced ubiquitination of pol η more acutely than the K→A mutations, we decided to re-evaluate the effect of a single K715R substitution, since the K715A mutant gave the greatest reduction in the levels of ubiquitination (Fig. 2). Again, the conservative K715R substitution diminished ubiquitination of pol η to a greater extent than K715A. In some regards, this is surprising, since one might expect that the extreme C-terminal residue would be exposed and there would not be a large structural effect of the alanine, or arginine substitutions.

Recent technical progress in mass spectrometry-based methods in combination with novel ubiquitin enrichment strategies using di-Gly-lysine specific antibody (41) have significantly increased the number of documented ubiquitinated proteins and pinpointed many of their ubiquitin-modified lysines on a global level, including many TLS proteins (6). Within the last four years, several groups have reported large-scale detection of lysine ubiquitination events in human cells and in nine of these studies ubiquitination sites of pol η have been identified (41-49).

Figure 4 summarizes all the lysine residues in pol η that have been shown to be ubiquitinated. In total, 27 lysine residues of pol η have been experimentally shown to be ubiquitinated. Based upon structural considerations, we have identified another three lysine residues that could potentially be ubiquitinated. Eight of the sites were detected just once. The remaining 19 ubiquitination sites in pol η were identified in anywhere between 2 to 6 independent studies, often using very different experimental strategies (e.g., ectopically expressed vs. chromosomally expressed pol η and/or different detection methods). However, no single site has been identified in all of the PTM studies. Thus, unlike pol η, which is ubiquitinated at one primary site and a handful of secondary sites (12), pol η does not appear to possess a primary site for ubiquitination, but is, instead, ubiquitinated at multiple lysine residues.

**Pol η ubiquitination in response to a variety of DNA damaging agents** - The 30 potential ubiquitination sites are distributed along the entire length of the pol η peptide. However, some are clustered in domains and motifs of pol η that are important for its cellular function in DNA damage tolerance (dRP lyase domain, catalytic polymerase domain, PIP, RIR, UBM1 and UBM2) (Fig. 4). We were therefore interested in determining if the ubiquitination status of pol η is influenced by exposure to DNA damaging agents. Indeed, there is a precedent for damage-induced de-ubiquitination of human pol η, so as to allow it to interact with ubiquitinated PCNA and facilitate TLS (12). We therefore examined pol η ubiquitination in response to treatment with agents that cause different types of DNA damage such as UV irradiation which results in both cyclobutane pyrimidine dimers and 6-4 photoproducts; ethyl methanesulfonate which generates alkylation damage (50); mitomycin C which generates interstrand crosslinks (51,52); and two oxidizing agents, potassium bromate and menadione (53,54). Somewhat surprisingly, most of the DNA damaging agents did not result in any significant change in the extent of pol η ubiquitination, even
Ubiquitination of polι

several hours after the initial treatment (Fig. 5A-D). In contrast, in cells treated with 30 µM menadione for one hour (time 0), we observed an increase of polι with much slower mobility, that is consistent with polyubiquitination of polι (Fig. 5E). Furthermore, the intracellular levels of pol decrease significantly 3-5 hours after treatment, suggesting that the posttranslationally modified polι protein is targeted for degradation.

Polι ubiquitination in response to treatment with various naphthoquinones and inhibitors of mitochondrial function - Our observation that potassium bromate did not elicit the same polyubiquitination of polι as menadione, suggests that polyubiquitination of polι is unlikely to occur as a result of oxidative damage per se, but occurs in specific response to menadione treatment. While both agents cause oxidative DNA damage, they do so by different mechanisms. For example, potassium bromate induces glutathione-mediated oxidative base damage (53), whereas menadione does so by inducing mitochondrial dysfunction, leading to an increase in reactive oxygen species (ROS) (54). However, we observed no significant increase in polι polyubiquitination after inhibition of the mitochondrial respiratory chain complex I with rotenone (55), or antimycin A, which inhibits cytochrome C reductase and the production of ATP (56) (Fig. 6), indicating that simple mitochondrial dysfunction is not the root cause for polι polyubiquitination.

In contrast, we discovered that polι polyubiquitination occurs after exposure to naphthoquinones that are structurally related to menadione (Fig. 7), including 1,4-naphthoquinone, juglone and plumbagin. Similar to menadione, all three compounds stimulated polι ubiquitination in a concentration-dependent manner (Fig. 7). A particularly strong effect was observed after exposure to low concentrations of juglone and plumbagin (Fig. 7C & D). However, another naphthoquinone, 2,3 dimethoxy-1,4-naphthoquinone (DMNQ) that also causes significant oxidative DNA damage (57) did not induce polι polyubiquitination (Fig. 8). Although the UV-induced ubiquitination/deubiquitination of polη and polι seem to be differentially regulated (c.f., (12) and Fig 5A), polη also appears to undergo polyubiquitination in response to menadione, and plumbagin treatment (unpublished observations). Whether this occurs as a result of a common pathway controlling the polyubiquitination of both polymerases in response to naphthoquinones remains to be determined.

Polι ubiquitination in response to treatment with an inhibitor of KAT3B/p300 - It is apparent that the effects of menadione, juglone, 1,4 naphthoquinone and plumbagin cannot be simply attributed to oxidative DNA damage, or mitochondrial dysfunction. However, naphthoquinones are also known to inhibit the activity of the lysine acetyltransferase KAT3B/p300 (58,59). We therefore considered the possibility that the inhibition of ubiquitin acetylation may promote the polyubiquitination of polι. To test this hypothesis, HEK293T cells were treated with the KAT3B/p300 inhibitor, L002. Indeed, similar to the effects of naphthoquinones, L002 results in the polyubiquitination of polι (Fig. 7E).

Mass spectrometry analysis of polyubiquitinated forms of polι - To further explore the nature of polyubiquitinated forms of polι appearing after treatment with naphthoquinones, we performed mass spectrometry analysis on the purified ubiquitin-conjugated polι. To do so, we used M2 anti-FLAG beads (Sigma) to pull-down N-terminal FLAG-tagged polι expressed in HEK293T cells that had been treated for 1 hour with 30 µM menadione (Fig. 7A), followed by tryptic digestion and LC-MS/MS analysis. This analysis was repeated twice, with independently prepared extracts and extracts from non-treated cells were used as controls. In control experiments, we predominantly observed monoubiquitinated forms of polι. In these extracts, we identified 7 ubiquitinated lysines (K87, K271, K283, K309, K486, K488 and K508). All of them except K508 were known as potential ubiquitination sites from previous approaches. Interestingly, in extracts prepared from menadione-treated cells, where intensive polyubiquitination of polι was observed, we identified four ubiquitinated lysines (K271, K309, K320 and K488) located in the N-terminal and central part of polι. Three of them, K271, K309 and K488, were identified in both independent
Ubiquitination of polι

...experiments. Since all four residues were previously indicated in our earlier experiments, or in proteome-wide experiments (40,42,43,46,47), as potential ubiquitination sites in untreated cells, we conclude that menadione treatment most probably causes polyubiquitination of polι at lysine residues that are already monoubiquitinated, rather than de novo at novel lysines.

In polyubiquitin chains, ubiquitins are linked to each other via an isopeptide bond between the C-terminal glycine of one ubiquitin and one of the lysine residues of the next ubiquitin. Ubiquitin contains seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) and all of them can become ubiquitinated to establish polyubiquitin chains of different shape and biological function [reviewed in (36)]. Mass spectrometry analysis of polyubiquitinated polι revealed that the polyubiquitin chains formed in response to menadione are formed via K11- and K48-linkages (Fig. 9B & 9C). Aside from these two peptides carrying a diglycine remnant, we also observed unmodified tryptic peptides derived from ubiquitin, including TLSDYNIQK (amino acid residues 55-63) and TITLEVEPSDTIENVK (amino acids residues 12-27). Moreover, we observed K11- and K48- linkages in polyubiquitinated polι obtained from plumbagin treated cells (unpublished observations). Presumably these linkages are formed in response to a common signal induced by exposure to naphthoquinones.

K48-linked polyubiquitin chains represent one of the most known and abundant ubiquitin linkages in the cell and target marked proteins to degradation by the 26S proteasome (60,61). The cellular role of the K11-linkage is less known, however the function of homogenous K11-linked polyubiquitin chains are also implicated in proteasomal degradation (62,63). Consistent with the notion that polyubiquitinated polι is subject to proteasomal degradation, we observed an increase in the background levels of polyubiquitinated polι in undamaged cells in the presence of the proteasome inhibitor, MG132 (Fig. 10).

Discussion

Ubiquitination is an important factor allowing for quick, controlled and reversible modification of a protein’s fate, cellular abundance, function, localization, and the promotion of protein-protein interactions. Several proteins employed in TLS are known to be ubiquitinated in vivo and the protein modification is used to adjust the specificity of TLS mechanisms in a variety of ways [reviewed in (6)].

It has been a decade since the discovery that human polι can be monoubiquitinated in vivo (11), yet the consequences of the modification remains enigmatic. Our previous studies, which show the dependence of a poli-polη interaction on the ubiquitination of either protein (13) provides some early insights into a possible role of polι modification.

In the present study, we have identified a number of lysine residues in polι that can be covalently linked to ubiquitin. Unlike polη, which is ubiquitinated at one primary site and a handful of secondary sites (6,12), we discovered that polι is ubiquitinated at more than 27 unique sites (Fig. 4). Two thirds of the identified sites were detected in multiple autonomous studies using different experimental strategies (e.g., ectopic expression of N- and C-terminal FLAG tagged polι vs. native untagged chromosomally expressed polι and different methods of identification). While we cannot exclude the possibility that polι is ubiquitinated at random sites, we believe that the detection of specific ubiquitination sites in multiple independent studies increases the probability that those sites are likely to play key roles in regulating the cellular activities of polι.

When assayed by SDS-PAGE, the predominant form of polι is a single mono-ubiquitinated species, rather than multiply mono-ubiquitinated forms of polι. We note that under certain conditions, such as when cells are exposed to menadione, we do observe a “laddering” of FLAG-tagged polι, indicative of multiple monoubiquitination events (Fig. 7), but we cannot distinguish between the possibility of multiple monoubiquitinations of polι, or a single monoubiquitination event that is subsequently converted into a polyubiquitin chain. Our observations therefore indicate that once polι is monoubiquitinated at one particular site, it subsequently precludes monoubiquitination at additional sites in polι. Clearly, this is an area of...
research that needs to be studied in detail and will be the subject of future studies.

No single K→A, or K→R substitution completely blocked monoubiquitination of pol. However a K→R substitution at K715 which is located at the very C-terminus of pol and which has been shown to be ubiquitinated in two independent proteome-wide approaches (43,49), gave the greatest reduction in monoubiquitination (Fig. 3). We predict that the structure of covalently-linked ubiquitin to K715 will position the ubiquitin moiety for a productive interaction with the UBM2 of pol (Fig. 11E). Similarly, ubiquitination at K522 may also facilitate an interaction between ubiquitin and UBM1 of pol (Fig. 11D). We hypothesize that such interactions may, in turn, help promote an interaction between pol and pol\textsubscript{η} (13).

In contrast, monoubiquitination of other lysine residues may have a detrimental effect on pol's cellular functions. For example, many sites are located in the catalytic domain of the polymerase and may alter both DNA binding properties and polymerase activity of pol (Fig. 4, 11A and Table 2). Ubiquitination sites were also identified in both the PIP-box (PCNA-interacting region) and the RIR motif (Rev1-interacting region) and it seems highly unlikely that pol would be able to physically interact with either PCNA, or Rev1, if these sites are ubiquitinated (Fig. 11B & 11C).

Unlike pol\textsubscript{η}, which is de-ubiquitinated upon UV-irradiation (12), the level of pol monoubiquitination remained constant after exposure to a variety of DNA damaging agents including UV-light, EMS, MMC, or the oxidative DNA damage inducers, potassium bromate (Fig. 5), rotenone and antimycin A (Fig. 6) and DMNQ, (Fig. 8). In dramatic contrast, menadione and several structurally related naphthoquinones, resulted in the rapid polyubiquitination of pol. Mass spectrometry of polyubiquitinated pol purified from menadione- and plumbagin-treated cells indicated that the polyubiquitin chains were formed through K11- and K48- linkages. Conjugation of ubiquitin via K48-linkage is well known to serve as a signal for proteasomal degradation (60,61). Indeed, the disappearance of pol 3-5 hours after exposure to menadione (Fig. 5E) is consistent with its degradation.

We initially considered that the signal triggering polyubiquitination of pol might be oxidative DNA damage, but this was rapidly excluded when we failed to observe polyubiquitination in response to potassium bromate (Fig. 5C), DMNQ (Fig. 8), rotenone, or antimycin A (Fig. 6). However, in addition to the induction of reactive oxygen species, the naphthoquinones are also known to exert a wide range of cellular effects leading to stress signaling, anti-angiogenesis and thiolate arylation of proteins and amines (64-66). One property of interest is their ability to inhibit the lysine acetyltransferase (KAT), p300 (58,59). All of the naphthoquinones (1,4-naphthoquinone, menadione, juglone, plumbagin) that induce pol polyubiquitination have previously been reported to inhibit the KAT activity of p300 (59). It is unknown whether DMNQ (which did not cause pol polyubiquitination), can inhibit the KAT activity of p300. However, since DMNQ lacks the critical hydroxyl group at the 5th position of the benzene ring that is required for inhibition of KAT activity (59) and the 2nd and 3rd positions that are normally subject to nucleophilic attack are occupied by methoxy groups (Fig. 8), we assume that it probably does not inhibit KAT activity.

It is now well established that acetylation is a key regulator of diverse biological processes, from metabolism to signaling and immunity (67). Indeed, like many proteins, ubiquitin is subject to acetylation (49,68). Interestingly, both K11- and K48- are moderately sensitive to acetylation (49,68). Thus, we hypothesize that if K11- and K48- of ubiquitin are acetylated, it would preclude the formation of polyubiquitin chains via these linkages. Our observation that the p300 inhibitor, L002, also induces polyubiquitination of pol strongly suggests that there is a competition between ubiquitination and acetylation at overlapping lysine residues in pol. We believe that such competition constitutes a novel mechanism to regulate the stability of pol that warrants further investigation.
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest with the contents of this article.

Author contributions—J.M. constructed all of the pJRM expression plasmids shown in Table 1, as well as designed, performed and analyzed the experiments shown in Figures 2, 3 and 4 and wrote the paper. M.P.M. performed and analyzed the experiments shown in Figures 1, 5, 6, 7, 8 and 10. E.G.F. prepared purified N-terminal FLAG-tagged pol1 for mass spectrometry analysis shown in Figure 4. X.D. and Y.W. designed, performed and analyzed the mass spectrometry experiments shown in Figure 4 and 9. W.Y. analyzed the structural ramifications of pol1 monoubiquitination shown in Figure 11 and Table 2. R.W. conceived and coordinated the study and wrote the paper. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

Ubiquitination of pol


Ubiquitination of polι


Ballmaier, D., and Epe, B. (1995) Oxidative DNA damage induced by potassium bromate under cell-free conditions and in mammalian cells. *Carcinogenesis* 16, 335-342


Ubiquitination of polι


**FOOTNOTE**

Funding for this work was provided by the National Institute of Child Health and Human Development/National Institutes of Health Intramural Research Program (to R.W.); National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health Intramural Research Program (to W.Y.); the Foundation for Polish Science HOMING PLUS/2013-7/10 (to J.M.), and the National Institutes of Health (R01 DK082779 to Y.W.).

1 The abbreviations used are: TLS, translesion DNA synthesis; pol, DNA polymerase; PCNA, proliferating cell nuclear antigen; PIP, PCNA interacting peptide motif; RIR, Rev1 interacting region; UBMs, ubiquitin binding motifs; PTM, posttranslational modification; EMS, ethyl methanesulfonate; MMC, mitomycin C; DMNQ, 2,3-dimethoxy-1,4-naphthoquinone
FIGURE LEGENDS

FIGURE 1. **Highly purified polι protein, purchased from Origene Technologies.** *A.* Commassie Brilliant Blue stained gel of FLAG-tagged polι purified from HEK293T cells. *B.* Western blot of purified polι. Polι was visualized using monoclonal antibodies to the FLAG epitope (track 1); polyclonal antibodies to polι (track 2); or monoclonal antibodies to polι (track 3). The images clearly show that the major band observed in the Commassie Brilliant Blue stained gel corresponds to native FLAG-polι. The slower migrating band also contains polι and appears to be a posttranslationally modified form of polι. The faster migrating band observed in panel A, does not appear to be related to FLAG-polι since it does not cross-react to either the FLAG or polι antibodies.

FIGURE 2. **Effects of K→A substitutions on the extent of polι ubiquitination in HEK293T cells.** *A.* Single amino acid substitutions. *B.* Multiple amino acid substitutions. 2K, (K704A/K715A); 4K, (K522A/K526A/K530A/K549A); 7K (K248A/K522A/K526A/K530A/K549A/K704A/K715A); 12K, (K237A/K245A/K248A/K267A/K271A/K522A/K526A/K530A/K549A/K550A/K704A/K715A). Upper panel; a representative western blot using monoclonal anti-FLAG antibodies. Lower panel; densitometric quantification of polι monoubiquitination. Data are the mean values from six (A) or three (B) independent experiments, ±SD.

FIGURE 3. **Effects of K→A and K→R substitutions on the extent of ubiquitination of polι in HEK293T cells.** *A.* Western blot using monoclonal anti-FLAG antibodies. *B.* Lower panel; densitometric quantification of polι monoubiquitination. Data are the mean values from four to five independent experiments, ±SD. Lysine residues were changed to either alanine or arginine. 19K; (K51/ K53/ K72/ K237/ K245/ K248/ K267A/ K271A/ K283/ K309/ K310/ K320/ K522/ K526/ K530/ K549/ K550/ K704/ K715); 12K, (K237/ K245/ K248/ K267/ K271/ K522/ K526/ K530/ K549/ K550/ K704/ K715); and the C-terminal K715 residue.

FIGURE 4. **Sites of ubiquitination in polι.** Lysine residues in polι that have been shown to be subject to ubiquitination are indicated with a colored dot. The reference for each residue is given below the primary amino acid sequence of polι. As noted, polι can be ubiquitinated at more than 27 unique lysine residues. Some residues have been observed in multiple studies, but no single residue has been identified in every study. The various motifs and domains in polι are identified by color-coded bars above the primary amino acid sequence.

FIGURE 5. **Effect of DNA damaging agents on the extent of polι ubiquitination in HEK293T cells.** *A.* UV-irradiation (resulting in cyclobutane pyrimidine dimers and 6-4 photoproducts); *B.* EMS (resulting in alkylation DNA damage); *C.* MMC (resulting in interstrand crosslinks); *D.* Potassium bromate (resulting in oxidative DNA damage) *E.* Menadione (believed to cause oxidative damage and a variety of other cellular effects). Polι was visualized in western blots using monoclonal antibodies to the N-terminal FLAG epitope. The major band is unmodified polι, followed by mono-ubiquitinated polι. Slower migrating proteins are believed to be polyubiquitinated forms of polι.

FIGURE 6. **Effect of rotenone or antimycin A on polι ubiquitination in HEK293T cells.** Cells were treated with the indicated amount of either rotenone, or antimycin A for 1 hr prior to harvesting. Polι was visualized in western blots using monoclonal antibodies to the N-terminal FLAG epitope. The major band is unmodified polι, followed by mono-ubiquitinated polι. Under these conditions, there was no significant induction of polyubiquitinated polι.
FIGURE 7. **Effect of various naphthoquinones and a lysine acetyltransferase inhibitor, L002, on the extent of polι polyubiquitination in HEK293T cells.** Cells were treated for 1 hr with the indicated concentration of each compound. A, menadione; B, 1,4 naphthoquinone; C, juglone; D, plumbagin; E, L002. Polι was visualized in western blots using monoclonal antibodies to the N-terminal FLAG epitope. All compounds lead to an increase in polyubiquitinated forms of polι, with the most dramatic effects observed with the naturally occurring naphthoquinone, plumbagin. The chemical structures of each compound are shown on the right-hand side of each panel.

FIGURE 8. **Comparison of menadione, or DMNQ treatment on polι ubiquitination in HEK293T cells.** Cells were treated with the indicated amount of either mendione, or DMNQ for 1 hr prior to harvesting. Polι was visualized in western blots using monoclonal antibodies to the N-terminal FLAG epitope. The panel depicting polι ubiquitination after menadione treatment is a slightly darker exposure of Fig. 7A, so as to highlight the laddering of the ubiquitinated forms of polι (as noted by arrowheads). Under these conditions, there was no significant induction of polyubiquitinated polι after treatment with DMNQ.

FIGURE 9. **Mass spectrometry analysis of ubiquitinated polι recovered from menadione–treated HEK293T cells.** A, Western blot of purified proteins recovered from untreated and menadione–treated cells. Note that the menadione-treated cell extract contains significantly more polyubiquitinated forms of polι than the untreated cell extract. Both extracts were subjected to mass spectrometry analysis. B, The MS/MS of the [M+2H]2+ ion of the peptide 43LIFAGKubiQLEDGR54 from menadione-treated polι samples showing the K48-linkage of ubiquitin. C, The MS/MS of the [M+2H]2+ ion of the peptide 7TLTGKubiTITLEVEPSDTIENVK27 from menadione-treated polι samples showing the K11-linkage of ubiquitin. ‘ubi’, ubiquitination.

FIGURE 10. **Effect of the proteasomal inhibitor MG132, on polι ubiquitination in HEK293T cells.** Cells were either untreated, or exposed to the proteasomal inhibitor, MG132, for the times indicated. Polι was visualized in western blots using monoclonal antibodies to the N-terminal FLAG epitope. In both cases, the major band is unmodified polι, followed by monoubiquitinated polι. We note that the intensity of polyubiquitinated polι increases over time, in the MG132 treated cells compared to untreated cells, suggesting that the basal level of polyubiquitinated polι is normally kept to a minimum by 26S proteasomal degradation.

FIGURE 11. **Diagram of ubiquitinated lysine residues in the three-dimensional structures of human polι.** A, The catalytic domain of human polι (1-420 amino acids) is shown in a ternary complex with DNA (purple tube-and-ladder) and an incoming dGTP (PDB: 3GV8) (29). The polι regions are always shown as a yellow cartoon with the lysine located near the functional interface highlighted as a dark blue stick. The lysines that are distal from a functional surface are shown in light blue. K320, whose ubiquitination may destabilize the protein structure, is shown in orange. Some lysine side chains are disordered and are thus modeled as alanine (K51, K83, K283 and K310). B, The PIP region of human polι. K421 is near the interface with the green subunit of the trimeric PCNA (the other two PCNA subunits are shown in pink and cyan behind the green subunit) according to the crystal structure (PDB: 2ZVM) (69). C, The RIR of human polι is modeled after the crystal structures of human and mouse polκ in a complex with REV1/3/7 (PDB: 4GK5 and 4FJO, respectively). Two lysine residues of the RIR (K549-K550) are conserved, but only one (K550), is near the interface with REV3 and forms a salt bridge with a conserved glutamate of REV1 (E1174 in human REV1). D, The UBM1 of human polι is modeled after the NMR structure of mouse UBM1 in a complex with ubiquitin (PDB: 2KWV) (70). K522 is hydrogen bonded with the main chain carbonyl oxygen of L71 in ubiquitin. E, UBM2 of human polι in complex with
Ubiquitination of pol1

ubiquitin is shown according to the NMR structure (PDB: 2L0F) (71). K715, the C-terminal residue of pol1 is near the interface with ubiquitin, while K697 and K704 are distal from ubiquitin.
### Table 1: Plasmids used in this study

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pJRM46</td>
<td>pCMV6AN-DDK-pol (N-terminal tag)</td>
<td>(13)</td>
</tr>
<tr>
<td>pRK7-POLI-3XFLAG</td>
<td>pRK7-3xFLAG-pol (C-terminal tag)</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM57</td>
<td>pCMV6AN-DDK-pol_ K248A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM48</td>
<td>pCMV6AN-DDK-pol_ K522A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM49</td>
<td>pCMV6AN-DDK-pol_ K526A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM50</td>
<td>pCMV6AN-DDK-pol_ K530A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM51</td>
<td>pCMV6AN-DDK-pol_ K549</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM52</td>
<td>pCMV6AN-DDK-pol_ K704A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM53</td>
<td>pCMV6AN-DDK-pol_ K715A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM226</td>
<td>pCMV6AN-DDK-pol_ K715R</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM54</td>
<td>pCMV6AN-DDK-pol_ K704A/K715A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM55</td>
<td>pCMV6AN-DDK-pol_ K522A/K526A/K530A/K549A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM89</td>
<td>pCMV6AN-DDK-pol_ K248A/K522A/K526A/K530A/K549A/K704A/K715A</td>
<td>this work</td>
</tr>
<tr>
<td>pJRM219</td>
<td>pCMV6AN-DDK-pol_ K237R/K245R/K248R/K267R/K271R/K522R/K526R/K530R/K549R/K550R/K704R/K715R</td>
<td>this work</td>
</tr>
</tbody>
</table>
Table 2: Location of ubiquitination sites in polI and their structural implications$^a$

**A: Polymerase Domain**
- K51: located in the finger domain, pointing towards the outside of the protein
- K53: located in the finger domain, pointing towards the outside of the protein
- K72: located in the finger domain, pointing towards the outside of the protein
- K87: located in the finger domain, ~20Å from the incoming nucleotide, may have some effect on catalysis
- K138: on the rear side of the protein, when looking at the active site of the polymerase
- K203: likely to effect DNA binding and overall structure of the polymerase
- K237: likely to effect DNA binding
- K245: likely to effect DNA binding
- K248: likely to effect DNA binding
- K267: on the rear side of the protein, when looking at the active site of the polymerase
- K271: ~15Å from the upstream DNA duplex, may have some effect on catalysis
- K283: on the rear side of the protein, when looking at the active site of the polymerase
- K309: may be involved in DNA binding, as it is ~8 Å from the downstream ssDNA
- K310: on the same face as DNA binding, but distal from DNA
- K320: near D306 and E323 for the structure stability and near the finger domain
- K389: on the same face of DNA binding, but distal from DNA

**B. PCNA interaction motif**
- K421: near the PCNA interface

**C. UBM1**
- K508: conserved in mouse (K506) and pointing away from the ubiquitin interface,
- K522: conserved in mouse (K520), forming a H-bond with ubiquitin
- K526: not conserved in mouse UBM1, N524 of mouse polI points away from the ubiquitin interface
- K530: not in the mouse UBM1 structure

**D. Rev1 Interacting Region**
- K549: pointing away from the interface with Rev1
- K550: close to the surface of Rev1

**E. UBM2**
- K697: pointing away from ubiquitin
- K704: pointing away from ubiquitin
- K715: C-terminal residue, not in UBM2 per se, but conjugation at this residue would likely position ubiquitin for a non-covalent interaction with UBM2.

$^a$: See Figure 11
Figure 1

1 - anti-Flag (Abnova)
2 - anti-iota, polyclonal
3 - anti-iota, monoclonal (Abnova)
McIntyre et al., Figure 3
Figure 5
McIntyre et al., Figure 6
McIntyre et al., Figure 9
McIntyre et al., Figure 11
DNA and Chromosomes:
Posttranslational Regulation of Human DNA Polymerase

Justyna McIntyre, Mary P. McLenigan, Ekaterina G. Frank, Xiaoxia Dai, Wei Yang, Yinsheng Wang and Roger Woodgate

J. Biol. Chem. published online September 14, 2015

Access the most updated version of this article at doi: 10.1074/jbc.M115.675769

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/early/2015/09/14/jbc.M115.675769.full.html#ref-list-1